A Guide To Myelofibrosis Clinical Trials
This actionable myelofibrosis guide lays out the considerations when managing your diagnosis to help you with the process and to make sure no step is missed along the way.
Myelofibrosis (MF) is a type of chronic leukemia and is one of the rarest forms of bone cancer. MF slowly replaces healthy bone marrow, which produces all blood cells, with scar tissue. When the bone marrow can no longer produce the needed amount of blood cells, symptoms such as anemia, weakness, bone pain, and fatigue emerge.
- 50-60% of all MF mutations associated with Janus Kinase 2 gene (JAK2) dysregulation
- 10-15% of all MF cases begin with Polycythemia Vera (PV) or essential thrombocythemia (ET)
Trials Can Help
Around 100 MF clinical trials are currently active in the United States. These trials are investigating new treatments and detection methods that could save lives in the future.
Current clinical trials are researching new:
- JAK inhibitors
- Histone deacetylase (HDAC) inhibitors
- Immunomodulatory drugs
- And more
Participating in a clinical trial not only progresses much needed research, but also gives patients access to these new innovative therapies years before the general population.
At Massive Bio, our mission is to enable cancer patients to have equal access to cutting-edge therapies and clinical trials, regardless of their location and/or financial stability.
Our Artificial Intelligence (AI) powered Clinical Trial Matching System connects patients and their treating oncologists to clinical trials according to their unique cancer case.
We enlist dedicated staff to collect medical records and treatment history and match patients to eligible trials near their home. We provide full support throughout your enrollment process to ensure logistics are handled so you can concentrate on your health.